{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-026924","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.702427+00:00","generated_at":"2026-05-31T21:44:11.254895+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"medium","headline":"Lixte Biotechnology switches director compensation from cash to stock options for Q2-Q4 2024 to preserve cash","bullets":["Director Rene Bernards agrees to receive equity compensation instead of cash starting Q2 2024, aligning with other non-officer directors.","Board Compensation Plan amended: non-officer directors will receive stock options for Q2, Q3, Q4 2024 in lieu of cash.","Options vest immediately, expire in 5 years; exercise price based on quarter-end closing market price.","Change intended to preserve cash; Board and Compensation Committee may extend beyond Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-026924","json":"https://secwatch.observer/filing/0001493152-24-026924.json","markdown":"https://secwatch.observer/filing/0001493152-24-026924.md","text":"https://secwatch.observer/filing/0001493152-24-026924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/0001493152-24-026924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:44:11.254895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}